COPENHAGEN, Denmark, Oct. 11, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of a EUR 54 million upsized financing. The financing includes investment from new investors EQT Life Sciences and OrbiMed, with participation from existing investors Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill Impact Ventures, Adjuvant Capital, Wellington Partners, Industrifonden, Sunstone LifeScience Ventures, and LF Invest. Vincent Brichard of EQT Life Sciences and Tal Zaks of OrbiMed will join the MinervaX Board of Directors.
Nearly a year after raising its largest financing so far, the Danish biotech MinervaX is back with an upsized financing round of €54 million ($57.3 million) to fund late-stage work for its vaccine against group B Streptococcus, the company announced Wednesday.
COPENHAGEN, Denmark, June 27, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of enrolment and initial dosing in its Phase 1, clinical vaccine trial in older adults. The trial is taking place at CEVAC (Centre for Vaccinology), Ghent University, Belgium.
COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.
A biotech 12 years in the making has secured its largest financing yet, and it has ambitious plans for what the chief executive called a “David vs. Goliath” venture.
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
COPENHAGEN, Denmark, Oct. 7, 2021 /PRNewswire/ -- MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces clinical progress on its maternal GBS vaccine as well as multiple additions to its leadership teams.